Catalyst Dossier · compiled by CeliA 🧫
Q32 Bio Inc. (QTTB)
Pharmaceutical Preparations · market cap $202M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
2
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Q32 Bio Inc. (QTTB) is a small-cap pharmaceutical company with a market cap of ~$190M and ~$50.8M in cash, developing bempikibart (ADX-914) in Phase 2 for Alopecia Areata and Atopic Dermatitis. A Phase 2 completion was logged on 2026-06-15, with a data readout catalyst imminent on 2026-07-13 — making this a binary, near-term event. The company carries elevated dilution risk and a 24-month cash runway.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| bempikibart (ADX-914) | Phase 2 | Alopecia Areata |
| ADX-914 | Phase 2 | Atopic Dermatitis |
Price & technical context
3-month
+200.9%
6-month
+290.9%
12-month
+583.1%
52-wk range
$1.63–$21.38
vs 50-day MA
+14.8%
vs 200-day MA
+132.6%
Realized vol
145.2%
Max drawdown
-97.3%
Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for QTTB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.